Search alternatives:
largest decrease » larger decrease (Expand Search)
marked decrease » marked increase (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
n decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
largest decrease » larger decrease (Expand Search)
marked decrease » marked increase (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
n decrease » _ decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(n = 3–4). Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. …”
-
7
KAP assessment scores (n = 422).
Published 2025“…Attitude improved from 16.76 (93.1%) at baseline to 17.74 (98.6%) at the six-week mark. …”
-
8
-
9
-
10
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…Summarized bar graphs showed EVO significantly decreased mRNA expression of pyroptotic markers (B) NLRP3 and (C) GSDM-D in CER treated P<sub>i</sub>-induced VSMCs. …”
-
11
-
12
Changes in the active H3K27ac and repressive H3K27me3 histone marks among Vasa2+/Piwi1+ and all cells in fed, starved, and refed juvenile polyps.
Published 2025“…Between fed, T<sub>5ds</sub> and T<sub>20ds</sub> timepoints, MFI levels of H3K27ac progressively and significantly decreased while levels H3K27me3 (M) did not change significantly (N). …”
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20